General Updates

26 August 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Submission of BRSR for the Financial Year 2025- 26 Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Business Responsibility and Sustainability Report (‘BRSR’) for the Financial Year 2025-26. The BRSR Report is also available on the Company’s website and at: https://www.cohance.com/wp- content/uploads/2026/08/Cohance_BRSR_2026.pdf Kindly take the above on record. Thanking You. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: a/a Business Responsibility and Sustainability Report SECTION GENERAL DISCLOSURE I. Details of the listed entity 1 NSE Symbol COHANCE 2 BSE Scrip Code 543064 3 ISIN INE03QK01018 4 Corporate Identity Number (CIN) of the Listed Entity L24299MH2018PLC422236 5 Name of the Listed Entity Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) 6 Date of Incorporation 06th November 2018 7 Registered office address 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai, Maharashtra 400093 8 Corporate address 202, A Wing, Galaxy Towers, Plot No 1, Hyderabad Knowledge City TSIIC Raidurg, Hyderabad, Telangana - 500081 9 E-mail investorservices@cohance.com 10 Telephone +91 40 23549414/ 3311 11 Website www.cohance.com 12 Financial year for which reporting is being done Start date End date Current Financial Year 1st April 2025 31st March 2026 Previous Financial Year 1st April 2024 31st March 2025 Prior to Previous Financial year 1st April 2023 31st March 2024 13 Name of the Stock Exchange(s) where shares are listed Details of the Stock Exchanges Sr. No. Name of the Stock exchange Description of other stock exchange Name of the Country 1. National Stock Exchange of India Limited (NSE) - India 2. BSE Limited (BSE) - India 14 Paid-up Capital (In C ) 38,25,67,140 15 Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report Name Himanshu Agarwal Whole-Time Director & Chief Financial Officer Contact +91 40-23549414 E mail investorservices@cohance.com Cohance Lifesciences Limited Statutory Reports 16 Reporting boundary - Are the disclosures under this report made on a standalone The disclosures under this report basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the are made on standalone basis. entities which form a part of its consolidated financial statements, taken together). 17 Whether the company has undertaken assessment or assurance of the BRSR Core? Yes, Reasonable Assurance 18 Name of assessment or assurance provider Company / LLP / Firm Company ID / LLP ID / Name of assessment or Designation of Date of Sr. No. Name* Firm Registration No.* assurance provider assessor or assurer signing 1. Sustainability Actions U74999HR2021PTC093811 Saket Sinha Director 05/08/2026 Private Limited 19 Type of assessment or assurance obtained Reasonable Assurance for all BRSR data points II. Products/ Services 20. Details of business activities (accounting for 90% of the turnover) Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Manufacturing Manufacture of pharmaceuticals, medicinal 95.72% chemical and botanical products 21. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover) Sr. No. Product/Service NIC Code % of total Turnover contributed 1. Manufacture of pharmaceuticals, medicinal chemical and 21009 95.72% botanical products III. Operations 22. Number of locations where plants and/or operations/offices of the entity are situated Location Number of plants Number of offices R&D centres Total National 13 2 5 20 International 0 1 0 1 23. Markets served by the entity A Number of locations Locations Number National (No. of States) 16 International (No. of Countries) 59 B What is the contribution of exports 84% as a percentage of the total turnover of the entity? C A brief on types of customers The Company is engaged in the Manufacture and Supply of Formulations, APIs, Drug Intermediates & Fine Chemicals catering to the needs of Global Pharma Industries including Contract Development and Manufacturing Organizations (CDMO). Our customers include the pharmaceutical companies. Annual Report 2025-26 IV. Employees 24. Details as at the end of Financial Year A. Employees and workers (including differently abled) Total Male Female Sr. No. Particulars (A) No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1 Permanent (D) 1,228 1,130 92.02% 98 7.98% 2 Other than permanent (E) 0 0 NA 0 NA 3 Total employees(D + E) 1,228 1,130 92.02% 98 7.98% WORKERS 4 Permanent (F) 1,583 1,451 91.66% 132 8.34% 5 Other than permanent (G) 2,240 1,890 84.38% 350 15.63% 6 Total workers (F + G) 3,823 3,341 87.39% 482 12.61% B. Differently abled Employees and Workers: Total Male Female Sr. No. Particulars (A) No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1 Permanent (D) 0 0 NA 0 NA 2 Other than Permanent (E) 0 0 NA 0 NA 3 Total differently abled employees (D + E) 0 0 NA 0 NA DIFFERENTLY ABLED WORKERS 4 Permanent (F) 0 0 NA 0 NA 5 Other than Permanent (G) 0 0 NA 0 NA 6 Total differently abled workers (F + G) 0 0 NA 0 NA 25. Participation/Inclusion/Representation of women No. and percentage of Females Total (A) No. (B) % (B / A) Board of Directors 10 2 20% Key Management Personnel 2 0 0% 26. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) Turnover rate in current FY (2025-26) Male Female Total Permanent Employees 17.2% 14.6% 17% Permanent Workers 15.9% 22.3% 16.5% Cohance Lifesciences Limited Statutory Reports Turnover rate in previous FY (2024-25) Male Female Total Permanent Employees 14.0% 14.9% 14.1% Permanent Workers 15.9% 21.8% 16.4% Turnover rate in the year prior to the previous FY (2023-24) Male Female Total Permanent Employees 17% 18.3% 17.1% Permanent Workers 25.4% 29.3% 25.6% Note: V. Holding, Subsidiary and Associate Companies (including joint ventures) 27. (a) Names of holding / subsidiary / associate companies / joint ventures Does the entity indicated at Name of the holding Indicate whether % of shares held column A, participate in the Sr. No. / subsidiary/associate holding/Subsidiary/ by listed entity Business Responsibility initiatives companies/joint ventures (A) Associate/Joint Venture of the listed entity? (Yes/No) 1. Cohance Lifesciences Inc., USA Wholly-owned Subsidiary 100% No 2. Sapala Organics Private Subsidiary Company 67.5% No Limited, India 3. NJ Bio Inc, USA Subsidiary Company 56% No 4. NJBIO India Pharmaceutical Subsidiary Company 100%1 No Private Limited, India 5. NJ Biotherapeutics, LLC, USA Subsidiary Company 100%1 No 6. Aruka Bio, Inc Associate Company 39.22% 2 No 1. Step - down wholly - owned subsidiary Company. Company’s subsidiary NJ Bio Inc is holding 100% shares of NJ Bio India Pharmaceuticals Private Limited and NJ Biotherapeutics, LLC. 2. Aruka Bio, Inc., is an associate company of the Company's subsidiary NJ Bio, Inc, therefore a step-down associate of the Company VI. CSR Details 28. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013 (Yes/No): Yes (ii) Turnover (in H Crore): 2504.43 (iii) Net worth (in H Crore): 4,267.77 Note: As CSR applicability is assessed based on the preceding financial year’s turnover and net worth, the relevant disclosure has been made for FY 2024–25. Annual Report 2025-26 VII. Transparency and Disclosure Compliances 29. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct FY ( [Showing first 8,000 characters — download PDF for full document]